Meropenem/Vaborbactam and Cefiderocol as Combination or Monotherapy to Treat Multi-Drug Resistant Gram-Negative Infections: A Regional Cross-Sectional Survey from Piedmont Infectious Disease Unit Network (PIDUN)

Meropenem/Vaborbactam and Cefiderocol as Combination or Monotherapy to Treat Multi-Drug Resistant Gram-Negative Infections: A Regional Cross-Sectional Survey from Piedmont Infectious Disease Unit Network (PIDUN)

Meropenem/vaborbactam (MV) and cefiderocol were recently approved by the Food and Drug Administration and European Medicines Agency and are among the most promising antibacterial in treatment regimens against multi-drug resistant (MDR) gram-negative bacilli. A survey with close-ended questions was p...

Full description

Bibliographic Details
Main Authors: Tommaso Lupia, Silvia Corcione, Nour Shbaklo, Giorgia Montrucchio, Ilaria De Benedetto, Valentina Fornari, Roberta Bosio, Barbara Rizzello, Simone Mornese Pinna, Luca Brazzi, Francesco Giuseppe De Rosa
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Journal of Functional Biomaterials
Subjects:
survey
meropenem/vaborbactam
cefiderocol
intensive care unit
stewardship
multi-drug resistant
Online Access:https://www.mdpi.com/2079-4983/13/4/174

Similar Items

Similar Items